Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2705 participants.
Also called NCT01289990
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,705 participants
- Registry
-
NCT01289990 -
2010-022718-17
-
- Other papers using this trial's data
- Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Mexico, Philippines, Slovakia, Slovenia, South Korea, Switzerland, Taiwan, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01289990. Non-randomized; double masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-07-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sitagliptin 100mg
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01289990- Content hash
589403619b97328d36ae41a4474712d4529bfe59c87feb9f74354bdcdaa91946